PMID: 7543478Aug 1, 1995Paper

Bicyclomycin sensitivity and resistance affect Rho factor-mediated transcription termination in the tna operon of Escherichia coli

Journal of Bacteriology
C Yanofsky, V Horn

Abstract

The growth-inhibiting drug bicyclomycin, known to be an inhibitor of Rho factor activity in Escherichia coli, was shown to increase basal level expression of the tryptophanase (tna) operon and to allow growth of a tryptophan auxotroph on indole. The drug also relieved polarity in the trp operon and permitted growth of a trp double nonsense mutant on indole. Nine bicyclomycin-resistant mutants were isolated and partially characterized. Recombination data and genetic and biochemical complementation analyses suggest that five have mutations that affect rho, three have mutations that affect rpoB, and one has a mutation that affects a third locus, near rpoB. Individual mutants showed decreased, normal, or increased basal-level expression of the tna operon. All but one of the resistant mutants displayed greatly increased tna operon expression when grown in the presence of bicyclomycin. The tna operon of the wild-type drug-sensitive parent was also shown to be highly expressed during growth with noninhibitory concentrations of bicyclomycin. These findings demonstrate that resistance to this drug may be required by mutations at any one of three loci, two of which appear to be rho and rpoB.

References

Mar 1, 1990·Journal of Bacteriology·W L DowningP P Dennis
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·J E MottT Platt
Nov 14, 1972·Journal of Molecular Biology·E N Jackson, C Yanofsky
Jan 1, 1966·Cold Spring Harbor Symposia on Quantitative Biology·F ImamotoC Yanofsky
Nov 14, 1966·Journal of Molecular Biology·C Yanofsky, J Ito
Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·J DeVito, A Das
Mar 1, 1994·Molecular Microbiology·T Platt

❮ Previous
Next ❯

Citations

Jul 3, 2015·Angewandte Chemie·Michael Georg HoeslNediljko Budisa
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·A B KhodurskyC Yanofsky
Aug 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jason M PetersRobert Landick
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·F GongC Yanofsky
Jun 7, 2005·Journal of Bacteriology·Valéria C S Italiani, Marilis V Marques
May 20, 2008·Journal of Bacteriology·Valley Stewart
Mar 28, 1998·Antimicrobial Agents and Chemotherapy·L CarranoP Alifano
Feb 16, 2002·Journal of Molecular Biology·O EspéliF Boccard
May 9, 2021·Applied Microbiology and Biotechnology·Tomás G VillaAngeles Sánchez-Pérez
Nov 1, 2005·EcoSal Plus·Larry Reitzer
Feb 15, 2005·Journal of Inorganic Biochemistry·Andrew P BroganHarold Kohn
Oct 28, 2004·Journal of the American Chemical Society·Vasant MuralidharanTom W Muir

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.